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Summary
Background—The evidence of the association between chronic obstructive pulmonary disease 
(COPD) and venous thromboembolism (VTE) is limited. There is no study investigating the 
association of restrictive lung disease (RLD) and respiratory symptoms with VTE.
Objectives—To investigate prospectively the association of lung function and respiratory 
symptoms with VTE.
Patients/Methods—In 1987–1989, we assessed lung function using spirometry and obtained 
information on respiratory symptoms (cough, phlegm and dyspnea) in 14 654 participants aged 
45–64, without a history of VTE or anticoagulant use, and followed them through 2,011. 
Participants were classified into four mutually exclusive groups, ‘COPD’ [forced expiratory 
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volume in 1 second (FEV1)/forced vital capacity (FVC)<lower limit of normal (LLN)], ‘RLD’ 
(FEV1/FVC≥LLN and FVC<LLN), ‘respiratory symptoms with normal spirometry’ (without RLD 
or COPD), and ‘normal’ (without respiratory symptoms, RLD or COPD).
Results—We documented 639 VTEs [238 unprovoked and 401 provoked VTEs]. After 
adjustment for VTE risk factors, VTE risk was increased for individuals with either respiratory 
symptoms with normal spirometry [Hazard ratio, (95% confidence interval): 1.40 (1.12–1.73)] or 
COPD [1.33 (1.07–1.67)] but not for those with RLD [1.15 (0.82–1.60)]. These elevated risks of 
VTE were derived from both unprovoked and provoked VTE. Moreover, FEV1 and FEV1/FVC 
demonstrated dose-response relations with VTE. COPD was more strongly associated with 
pulmonary embolism than deep venous thrombosis.
Conclusions—Obstructive spirometric patterns were associated with an increased risk of VTE, 
suggesting that COPD may increase the risk of VTE. Respiratory symptoms may represent a novel 
risk marker for VTE.
Keywords
Venous thromboembolism; lung function; chronic obstructive pulmonary disease; restrictive lung 
disease; respiratory symptoms
INTRODUCTION
Several studies have reported that chronic obstructive pulmonary disease (COPD), especially 
an acute exacerbation of COPD, is a risk factor for venous thromboembolism (VTE) [1–4]. 
However, most information on the association of COPD with VTE risk in the general 
population relies on results from registry-based studies, with no validation of VTE diagnoses 
[5]. A recent prospective population-based cohort study investigated the association between 
COPD and validated VTE risk [5]. The results suggested that patients with severe COPD 
may have increased risk of “provoke” VTE, but the association was not statistically 
significant [5]. In addition, this population-based study used the fixed 0.70 cut-off of forced 
expiratory volume in 1 second/forced vital capacity (FEV1/FVC) [5]. Using a fixed cut-off 
leads to underdiagnosis in young adults and overdiagnosis of airway obstruction in adults 
aged over 40 years, and as a result using the the 5th percentile of distribution as the lower 
limit of normal (LLN) is recommended [6, 7]. Thus, evidence for a relation between COPD 
and VTE remains limited.
Although potential mechanisms by which COPD might cause VTE remain unclear, 
hypercoagulability, inflammation, immobilization, and pulmonary hypertension with venous 
stasis due to impaired lung function and hypoxia are candidate risk mediators [1]. Other 
respiratory impairments, such as restrictive lung diseases (RLD), may also increase the risk 
of VTE via similar mechanisms, but to the best of our knowledge no epidemiological study 
has reported the prospective association between VTE and respiratory impairments other 
than COPD.
Here, using two important markers for respiratory impairment, lung function measured by 
spirometry and respiratory symptoms, we prospectively investigated whether respiratory 
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impairments (lung restriction, airway obstruction, and others) defined by the LLN are related 
to the risk of VTE in a population-based study in the U.S.
METHODS
Study Population
The Atherosclerosis Risk in Communities (ARIC) Study is an ongoing population-based 
prospective study of cardiovascular diseases [8]. The ARIC Study recruited and examined 
15 792 mostly Caucasian or African American men and women aged 45–64 from 4 U.S. 
communities (Washington County, Maryland; Forsyth County, North Carolina; Jackson, 
Mississippi (African Americans only); and suburbs of Minneapolis, Minnesota) in 1987–
1989 (visit 1). The institutional review boards of the collaborating institutions approved the 
study protocol, and each participant provided written informed consent.
For the present analyses, we excluded participants who reported a history of VTE or were 
taking anticoagulants at baseline survey (n=349), participants whose data on main exposure 
(n=188) or any covariates (n=837) were missing. We further excluded non-white participants 
in Washington County or Minneapolis or non-white/black participants in Forsyth County 
(n=54) in order to allow multivariable adjustment for race and study site [9]. After 
exclusions, 14 364 participants were included in the present analyses.
Main Exposure: Lung Function and Respiratory Symptoms
Spirometry was conducted at baseline using a water-sealed Collins Survey II volume 
displacement spirometer (Collins Survey II; Collins Medical; Braintree, MA) and Pulmo-
Screen II software (Pulmo-Screen; PDS Healthcare Products; Louisville, CO). At least 3 
acceptable spirograms were sought from a minimum of 5 forced expirations. The best single 
spirogram was identified by a computer and confirmed by a technician according to 
American Thoracic Society guidelines, using a standardized protocol [10]. Quality control 
was conducted carefully throughout the study [10]. FEV1 as a percentage of predicted value 
(FEV1 % predicted), FVC as a percentage of predicted value (FVC % predicted), and LLN 
were calculated using the Hankinson 1999 equations [11]. Bronchodilator (beta-agonist) 
response was not evaluated at visit 1.
Assessment of respiratory symptoms was based on responses to a standardized self-
administered questionnaire adopted from the Epidemiology Standardization Project [12]. We 
chose three representative respiratory symptoms (cough, phlegm and dyspnea) based on 
GOLD report [13] and COPD Foundation Guide [14]. Participants were considered as 
having respiratory symptoms if they responded positively to any of the following questions: 
‘Do you usually have a cough?’ (defined here as ‘cough’); ‘Do you usually bring up phlegm 
from your chest?’ (defined here as ‘phlegm’); and ‘Do you have to walk slower than people 
of your age on the level because of breathlessness?’ or ‘Are you too breathless to leave the 
house or breathless on dressing or undressing?’ (yes to either, defined here as ‘dyspnea’).
We classified participants into 4 categories, ‘normal’ was defined as those with FEV1/
FVC≥LLN, FVC≥LLN and no respiratory symptoms, ‘respiratory symptoms with normal 
spirometry’ as those with respiratory symptoms but FEV1/FVC≥LLN and FVC≥LLN, 
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‘restrictive lung disease pattern’ as FEV1/FVC≥LLN and FVC<LLN, and ‘COPD pattern’ as 
FEV1/FVC<LLN [7]. We included ‘respiratory symptoms with normal spriometry’ in the 
present analysis because others have documented adverse health outcomes among people in 
this category [15], and this category may reflect lung diseases with preserved lung function 
or borderline RLD or COPD.
Potential Confounding Factors
We evaluated a number of potential confounding factors, assessed at baseline, for the 
association of respiratory impairments with VTE. They included age (continuous), sex, race/
ARIC field center (whites in Washington County, Forsyth County, or Minneapolis, or 
African Americans in Jackson or Forsyth County), body mass index (BMI) calculated as 
weight (kg)/height (m)2 (continuous), prevalent diabetes, smoking status (current, former or 
never), pack-years of cigarettes smoked (continuous), estimated glomerular filtration rate 
(eGFR) (continuous), sport index (continuous) and steroid inhaler use. We included steroid 
inhaler use as a potential confounding factor because some patients with lung diseases 
receive steroid inhaler treatments, and several previous reports have suggested a positive 
association between steroid use and VTE risk [16, 17]. Prevalent diabetes was defined as a 
fasting blood glucose of 126 mg/dl or higher, non-fasting blood glucose of 200 mg/dl or 
higher, a self-reported physician diagnosis of diabetes, or use of antidiabetic medication in 
the past 2 weeks. Pack-years of cigarettes smoked was calculated as the average number of 
cigarettes smoked per day times the number of years of smoking divided by 20 (the number 
of cigarettes in a pack). eGFR was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation [18, 19]. Sport index was assessed using 
the Baecke sports questionnaire, with scores ranging from 1 (low) to 5 (high) [20].
Confirmation of Venous Thromboembolism
ARIC contacted participants annually or semi-annually by phone to ask about all 
hospitalizations in the previous year. Using standard criteria, two physicians validated 
possible VTEs using hospital records of possible VTE cases reported through 2011 [21]. 
Secondary VTEs associated with cancer, major trauma, surgery or marked immobility were 
classified as ‘provoked VTE’ while all others were classified as ‘unprovoked VTE’. 
Pulmonary embolism (PE) or deep venous thrombosis (DVT) was diagnosed using imaging 
tests.
Statistical Analysis
The person-years of follow-up for each participant were calculated from the baseline (1987–
1989) to the first endpoint: VTE, death, loss to follow-up, or the end of follow-up (2011). 
Hazard ratios (HRs) and their 95% confidence intervals (CIs) of VTE occurrence were 
calculated after adjustment for potential confounding factors using Cox proportional hazard 
models. Model 1 adjusted for age, sex, and race/ARIC field center; Model 2 additionally for 
body mass index, prevalent diabetes, smoking status, pack-years of cigarettes smoked, 
eGFR, sport index, and steroid inhaler use. We constructed cubic spline graphs with 3 knots 
at 25, 50 and 75 percentiles in order to examine dose-response relationships between 
FEV1 % predicted, FVC % predicted or FEV1/FVC and VTE risk.
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For sensitivity analyses, we further adjusted Model 2 for (i) self-reported diagnosis of 
bronchitis, emphysema and asthma, prevalent heart failure and coronary heart disease, or (ii) 
competing risks of death from underlying causes other than VTE or (iii) competing risks of 
arterial vascular diseases (coronary heart disease, heart failure, atrial fibrillation and stroke) 
which may require antithrombotic treatments [22]. We also (iv) ran models using shorter-
follow-up time for VTE (5 years from baseline).
The proportional hazards assumption in Cox regression was tested using risk factor-by-time 
interactions and was not violated. Since we found no statistical interactions between sex or 
race and main exposures in relation to VTE risk, an analysis pooled across sex and race was 
conducted. SAS version 9.3 software (SAS Institute Inc., Cary, NC) was used for statistical 
analyses. All statistical tests were two-tailed and P values < 0.05 were regarded as 
significant.
RESULTS
Baseline Characteristics According to Lung Function Categories
Among the 14 364 ARIC participants included in the analysis, the mean age was 54.1 years, 
54.9% were female, and 25.7% were African Americans. The prevalences of normal, 
respiratory symptoms with normal spirometry, RLD pattern, and COPD pattern were 63.8%, 
13.2%, 5.9%, and 17.4%, respectively. As shown in Table 1, those with respiratory 
symptoms or any of the abnormal spirometric patterns were more likely to be older, current 
smokers, have more pack-years and lower sports indices, and have reported diagnosis of 
bronchitis, emphysema or asthma, and history of coronary heart disease and heart failure 
than those with normal spirometry and no respiratory symptoms. Those with the RLD 
pattern were more likely to be obese and diabetic than the other categories.
Associations of Respiratory Categories with Venous Thromboembolism
During 284 969 person-years of follow-up, over a median of 22.5 years, we documented 639 
incident cases of VTE (238 unprovoked and 401 provoked) (Table 2). In the age, sex, and 
race-adjusted model (Model 1), participants with respiratory symptoms and normal 
spriometry, with the RLD pattern, or with the COPD pattern had a higher risk of VTE than 
those with normal spirometric results and no respiratory symptoms. After adjustment for the 
other risk factors (Model 2), participants with respiratory symptoms and normal spirometry 
had significantly increased risks of total VTE [HR (95% CI): 1.40 (1.12–1.73)], deriving 
from both unprovoked VTE [1.33 (0.93–1.91)] and provoked VTE [1.44 (1.10–1.89)], and 
both PE [1.33 (0.97–1.83)] and DVT [1.47 (1.09–1.97)]. Those with the RLD pattern had an 
elevated risk of unprovoked VTE [1.52 (0.93–2.49)] that was not statistically significant. 
Those with the COPD pattern had increased risk of total VTE [1.35 (1.08–1.68)]–both 
unprovoked [1.50 (1.05–2.14)] and provoked VTE [1.25 (0.94–1.67)], and were more likely 
to have increased risk of PE [1.49 (1.09–2.05)] than DVT [1.20 (0.87–1.65)]. No 
significantly increased risk of cancer-related VTE was observed among those with 
respiratory symptoms and normal spriometry [1.28 (0.85–1.93)], with the RLD pattern [0.67 
(0.31–1.46)], or with the COPD pattern [1.30 (0.87–1.96)] (not shown in Table 2).
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Dose-response Relations between Spirometry Measurements and Venous 
Thromboembolism
In order to examine how the degree of lung restriction or airway obstruction was associated 
with VTE risk, the continuous relations of FEV1 % predicted, FVC % predicted, and 
FEV1/FVC with VTE incidence were plotted using restricted cubic splines (Figure). Dose-
response relations were generally observed, with lower levels of FEV1/FVC and FEV1 
significantly associated with elevated risks of total VTE.
Sensitivity Analyses
For sensitivity analyses, first we further adjusted for self-reported diagnoses of bronchitis, 
emphysema and asthma, prevalent heart failure or coronary heart disease (data not shown), 
competing risks of death from underlying causes other than VTE (Model 3 in Table 2), or 
competing risks of arterial vascular diseases (data not shown) and found almost identical 
associations between lung function and VTE risk. Next, we ran models using shorter follow-
up intervals (within 5 years from baseline). Similar trends were observed although the 
analyses were less likely to be statistically significant, due to the smaller number of VTE 
events (49 cases for 5 years follow-up) (Supplementary Table and Figures).
DISCUSSION
In this prospective population-based cohort study, participants with respiratory symptoms 
but normal spirometric pattern and obstructive spirometric patterns had increased risk of 
VTE. The previous study reported elevated risk of only provoked VTE among those with 
obstructive spirometric pattern [5], but in the present study, we found they had increased 
risks of not only provoked but also unprovoked (not secondary) VTE. In addition, lower 
FEV1 % predicted and FEV1/FVC, indices of airway obstruction, were associated with 
elevated risk of VTE. To the best of our knowledge, this is the first prospective population-
based cohort study to investigate the association of lung function and respiratory symptoms 
with VTE occurrence, and to suggest that respiratory symptoms may be a risk marker for 
VTE. Furthermore, we provided further evidence on that COPD may increase the risk of 
VTE.
COPD involves pulmonary and systemic inflammation [23, 24]. Inflammation induced 
hypercoagulability, hypoxia, pulmonary hypertension, and venous stasis from immobility all 
might increase risk of VTE [1]. In the present study, those with COPD pattern had increased 
risk of unprovoked VTE, which may be explained by these mechanisms. As previous 
registry-based studies have suggested, our study also showed COPD pattern was associated 
with PE rather than DVT [5]. This may be partially because COPD patients often may be 
given CT scans, and thus be more likely to be diagnosed with PE (referral bias). In addition, 
cubic spline graphs suggested inverse dose-response relationships of FEV1 % predicted and 
FEV1/FVC with VTE. COPD is characterized by reduced FEV1/FVC [25]. Thus, these 
results support the hypothesis that COPD may increase the risk of VTE.
Those with the RLD pattern also had increased risk of unprovoked VTE, but the association 
was not significant. Possible reasons for this may be that the number of participants with the 
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RLD pattern (n=847 versus 2499 with COPD pattern) was insufficient, and perhaps the RLD 
pattern was also closely related to comorbidities, such as obesity and diabetes [26, 27]. 
Thus, a further study will be needed on the association between RLD and VTE risk.
Participants with respiratory symptoms and a normal spirometric pattern also had increased 
risk of VTE, particularly provoked VTE (Model 3 in Table 2). We speculate that their 
increased risk of VTE may be mainly due to immobility, cancer, heart failure, borderline 
COPD, or other comorbidities. Of course, respiratory symptoms would not be a causal risk 
factor for VTE but a marker for such comorbidities. Although our further adjustment for 
prevalent heart failure did not change the result, we cannot negate bias from undiagnosed 
heart failure (residual confounding) as heart failure with preserved ejection fraction is hard 
to diagnose [28]. In addition, those with respiratory symptoms and a normal spirometric 
pattern had an increased risk of cancer-related VTE (HR 1.28), although the association was 
not significant. In any case, respiratory symptoms may be a noteworthy marker of increased 
risk of VTE.
Although several previous studies have demonstrated associations of reduced spirometry 
measurements with increased risks of cardiovascular diseases, such as coronary heart disease 
[29], heart failure [30], stroke [31], or atrial fibrillation [32], no study has shown a relation 
of lung function with VTE risk. These previous studies have reported that FEV1 was 
associated with increased risk of cardiovascular diseases, but FEV1/FVC was not. Thus, 
VTE might be more strongly associated with airway obstruction than are other 
cardiovascular diseases.
The strengths of our study include its prospective design, a long follow-up, and validated 
VTE events. In addition, we used the LLN spirometry measurements, not fixed cut-offs, to 
define RLD and COPD, which theoretically reduced misclassification of exposures.
Nonetheless, some limitations need to be addressed. First, although we assumed the 
obstructive spirometric pattern was mainly COPD, as in other epidemiological studies [5, 15, 
33, 34], only pre-bronchodilator measurements were available. Thus, some participants 
without lung disease might have been included in the obstructive category, but this 
misclassification would tend to bias the results toward the null and do not readily explain the 
observed associations. In addition, we did not have data on total lung capacity, which is 
needed to meet the strict definition of restrictive lung disease [35]. Next, our follow-up was 
quite long and the lung function values and symptoms at baseline certainly would have 
changed during follow-up. Although both results from long and short-term (5 years) follow-
ups showed similar trends, we cannot negate the possibility of exposure misclassification 
especially among participants with respiratory symptoms and a normal spirometry because 
respiratory symptoms are subjective unlike spirometry. Some of participants’ symptoms 
might have stopped over time, while others might have developed COPD. The former case 
could have led to an overestimation of the risk of VTE and the latter, an underestimation. 
Those with a COPD or RLD pattern might have returned to normal lung function over time 
because of e.g. treatment, and this would led to an underestimation of the risk of VTE. 
Finally, the possibility of residual confounding of the observed associations cannot be 
Kubota et al. Page 7
J Thromb Haemost. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
negated, although the extent of potential bias is likely small given our detailed adjustment 
for many known confounders.
In conclusion, in the prospective population-based ARIC cohort, obstructive spirometric 
patterns (COPD pattern, low FEV1 and low FEV1/FVC) were associated with an elevated 
risk of VTE, suggesting that COPD may increase the risk of VTE. Furthermore, the presence 
of respiratory symptoms might be a novel risk marker for VTE. Those with the RLD pattern 
also had an increased risk of VTE, but the association was not significant, perhaps because it 
is closely related to comorbidities.
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Essentials
• The association of lung function with venous thromboembolism (VTE) is 
unclear.
• Chronic obstructive pulmonary disease (COPD) pattern were associated with 
a higher risk of VTE.
• Symptoms were also associated with a higher risk of VTE, but a restrictive 
pattern was not.
• COPD may increase the risk of VTE. Respiratory symptoms may be a novel 
risk marker for VTE.
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Figure. 
Multivariable adjusted (Model 2) associations of FEV1 as a percentage of predicted value 
(FEV1 % predicted), FVC as a percentage of predicted value (FVC % predicted), or 
FEV1/FVC with total VTE. Solid and dashed lines represent hazard ratios and 95% 
confidence interval, respectively. The reference value was the median value of the fourth 
quartile (87.5th percentile).
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